Decernotinib |
|
| Synonyms: (R)-2-((2-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl)amino)-2-methyl-N-(2,2,2-trifluoroethyl)butanamide;VX-509;VX509;VX 509 | |
| Cat. No.: D99500 | CAS No.: 944842-54-0 |
| MDL.: | Formula: C18H19F3N6O |
| F.W.392.4 | Purity: 99％ |
| Storage: Store at 0°C (short term), -20°C (long term) | |
| Size/Unit | Price | Qty | Availability | Price Total |
|---|---|---|---|---|
| 1mg | POA | Enter qty and click checkbox |
| Catalog Number： | D99500 | CAS No.: | 944842-54-0 | |
| MDL: | Formula: | C18H19F3N6O | ||
| F.W.: | 392.4 | Purity: | 99％ | |
| Package: | Unit: | mg | ||
| Appearance: | A crystalline solid | M.P.: | ||
| B.P.: | Density: | |||
| Optical Rotation: | Refractive Index: | |||
| Solubility: | Soluble in DMSO | Stability: | ||
| Storage: | Store at 0°C (short term), -20°C (long term) | Category: | Reference Standard | |
| Reference: | 1. S. Mahajan, et al, VX-509 is a potent and selective Janus kinase 3 (JAK3) inhibitor that attenuates inflammation in animal models of autoimmune disease. J .Pharmacol Exp Ther. 2015 May;353(2):405-14. doi: 10.1124/jpet.114.221176. Epub 2015 Mar 1 | |||
| Application: | Decernotinib (VX-509; VRT-831509, Adelatinib) is an orally bioavailable Janus kinase 3 (JAK3) inhibitor, potently and selectively inhibiting the enzyme with an in vitro Ki of 2.5 nM, and IC50 of 50-170 nM in cellular assays dependent on JAK3 activity. Highly selective, displaying no activity (with limited or no measureable potency) towards other JAK and non-JAK enzymes. Showed in vivo activity in two animal models of aberrant immune function, and demonstrated dose-dependent reduction in ankle swelling and paw weight and improved paw histopathology scores in the rat collagen-induced arthritis model (ref.1). | |||
| Category: | ||||